WangH, GuanL, DengM. Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. Front Neurosci, 2023; 17:1170996.
2.
FunayamaM, NishiokaK, LiY, et al.Molecular genetics of Parkinson’s disease: Contributions and global trends. J Hum Genet, 2023; 68:125–130.
3.
StanleyT, CrookeTC, JeffreyB, et al.Genotypic and phenotypic analysis of 173 patients with extremely rare pathogenic mutations who applied for experimental antisense oligonucleotide treatment. medRxiv, 2024.
4.
CrookeST, BakerBF, CrookeRM, et al.Antisense technology: An overview and prospectus. Nat Rev Drug Discov, 2021; 20:427–453.
5.
CrookeST, LiangX-H, BakerBF, et al.Antisense technology: A review. J Biol Chem, 2021; 296:100416.
6.
FreierSM, WattAT. Basin principles of antisense drug discovery. In: Antisense Drug Technology—Principles, Strategies, and Applications (CrookeST. eds.) CRC Press: Boca Raton, FL, 2006, pp. 117–141.
7.
LimaW, WuH, CrookeST. The RNase H mechanism. In: Antisense Drug Technology—Principles, Strategies, and Applications (CrookeST. eds.) CRC Press: Boca Raton, FL, 2008, pp. 47–74.
8.
ZarubinT, HanJ. Activation and signaling of the p38 MAP kinase pathway. Cell Res, 2005; 15(1):11–18.
9.
PianJMY, OwusuN, VitarelloJ, et al.How to pay for individualized genetic medicines. Nat Med, 2024; 30:1816–1818.
10.
ShiehPB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics, 2018; 15(4):840–848.
